From Wikipedia, the free encyclopedia
Jump to: navigation, search
Capreomycin IA.svg
Capreomycin IB.svg
Systematic (IUPAC) name
(3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(4R)-2-amino-3,4,5,6-tetrahydropyrimidin-4-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide; (3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(4R)-2-amino-3,4,5,6-tetrahydropyrimidin-4-yl]-8-[(carbamoylamino)methylidene]-2-methyl-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide
Clinical data
AHFS/ monograph
MedlinePlus a682860
  • C
Legal status
Routes intramuscular
CAS number 11003-38-6 YesY
ATC code J04AB30
PubChem CID 3032400
DrugBank DB00314
ChemSpider 21106276 YesY
KEGG D00135 N
NIAID ChemDB 007653
Chemical data
Formula C25H44N14O8 
Molecular mass 668.706 g/mol
 N (what is this?)  (verify)

Capreomycin is a peptide antibiotic, commonly grouped with the aminoglycosides, which is given in combination with other antibiotics for MDR-tuberculosis. Adverse effects include nephrotoxicity and 8th cranial auditory vestibular nerve nerve toxicity.

The drug should not be given with streptomycin or other drugs that may damage the auditory vestibular nerve. Patients on this drug will often require audiology tests.

It is a cyclic peptide. Capreomycin is administered intramuscularly and shows bacteriostatic activity.[1] Capreomycin was discovered in 1960, isolated from Streptomyces capreolus[2]

Spectrum of susceptibility[edit]

Capreomycin is frequently used to treat Mycobacterium tuberculosis infections. Mycobacterium tuberculosis growth has been found to be inhibited at a concentration of 2.5 μg/mL.[3]


  1. ^ "Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 2'-O-methylations in 16S and 23S rRNAs". Mol. Cell 23 (2): 173–82. July 2006. doi:10.1016/j.molcel.2006.05.044. PMID 16857584. 
  2. ^ Tomlinson, Catherine. "TB Online - Capreomycin". Retrieved 14 September 2014. 
  3. ^